The 2011 Leading Pharmaceutical Companies Strategic Directions

Complete report $1,850.  Individual company assessments $250.

For each company, the report provides insightful strategic assessments, including:

• Major strengths and weaknesses.
• Business, new product development, and marketing objectives and strategies.
• Anticipated acquisitions, joint ventures and divestitures.

        -   Abbott
        -   AstraZeneca
        -   Eli Lilly
        -   GlaxoSmithKline
        -   Johnson & Johnson
        -   Merck
        -   Novartis
        -   Pfizer
        -   Roche
        -   Sanofi-Aventis 

Contains 45 pages